Yashoda Hospitals Hyderabad Showcases Significant Advancements in Pulmonology

News Desk, News Nation 360: In order to highlight its historic clinical accomplishments and solidify its position as one of India's leading facilities for cutting-edge respiratory, thoracic, and transplant treatment, Yashoda Hospitals Hyderabad arranged a thorough media engagement in Kolkata. In addition to marketing executives Sanjay Bhattacharya and Sagar Mukherjee, an expert medical panel led by Dr Manjunath Bale (Consultant Robotic and Minimally Invasive Thoracic Surgeon) and Dr J. V. S. Aswith Chowdary (Consultant Clinical & Interventional Pulmonologist, Allergy & Immunology Specialist) presented the hospital's strategic commitment to increasing access to top-notch medical care for patients throughout Eastern India. The experts emphasised how advanced bronchoscopy, interventional pulmonology, and a dedicated Lung Nodule Clinic for early-stage lung cancer detection are significantly improving clinical outcomes and patient quality of life in response to the rising domestic burden of asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and cancers. The thoracic team at Yashoda Hitec City successfully completed India's first uniportal (single-port) robotic thoracic surgery, and they are still among the few domestic institutions that provide specialised Hyperthermic Intra-Thoracic Chemotherapy (HITHOC) and complex tuberculosis surgeries, according to Dr Bale's detailed account of the department's groundbreaking technological achievements. With the support of a cutting-edge infrastructure that includes ECMO support systems, specialised transplant intensive care units, and modular operating rooms, Yashoda Hospitals has solidified its pioneering legacy through a number of historic transplant breakthroughs. In 2012, it carried out the first lung transplant in the Telugu states, the first combined heart-lung transplant in Andhra Pradesh and Telangana, and it accomplished a worldwide medical milestone by successfully performing India's first double lung transplant for rare paraquat poisoning. The institution's comprehensive Heart & Lung Transplant Program currently boasts an 80–85% one-year post-transplant survival rate, presenting clinical outcomes that are directly comparable to leading globally benchmarked transplant centres. During the COVID-19 pandemic, the program managed one of the largest volumes of air-evacuated, critically ill respiratory patients in the country.

Pic - Krishnendu Kundu